The FDA panel, in a 13-to-1 vote, overwhelmingly ruled against Depomed's drug,
saying clinical data failed to show the product was effective. Then the panel,
in a 12-to-2 vote, ruled the overall risk-benefit profile wasn't acceptable to
support marketing of the product. The panel, which is made up of non-FDA medical
experts, will vote on Hisamitsu's drug later Monday.
Looking for a quick short and a little bounce at the open
No comments:
Post a Comment